QQQ   305.02 (-0.11%)
AAPL   157.37 (+1.53%)
MSFT   271.24 (-2.93%)
META   196.92 (+0.67%)
GOOGL   101.08 (-0.53%)
AMZN   96.62 (-2.35%)
TSLA   183.21 (+1.71%)
NVDA   259.58 (+0.91%)
NIO   8.66 (+4.84%)
BABA   80.73 (-1.15%)
AMD   95.49 (-2.40%)
T   18.45 (+1.77%)
F   11.23 (-0.62%)
MU   57.14 (+0.85%)
CGC   1.89 (-5.50%)
GE   90.01 (-0.31%)
DIS   93.69 (+0.53%)
AMC   4.25 (+1.67%)
PFE   40.57 (+1.17%)
PYPL   72.58 (-0.56%)
NFLX   303.59 (+0.03%)
QQQ   305.02 (-0.11%)
AAPL   157.37 (+1.53%)
MSFT   271.24 (-2.93%)
META   196.92 (+0.67%)
GOOGL   101.08 (-0.53%)
AMZN   96.62 (-2.35%)
TSLA   183.21 (+1.71%)
NVDA   259.58 (+0.91%)
NIO   8.66 (+4.84%)
BABA   80.73 (-1.15%)
AMD   95.49 (-2.40%)
T   18.45 (+1.77%)
F   11.23 (-0.62%)
MU   57.14 (+0.85%)
CGC   1.89 (-5.50%)
GE   90.01 (-0.31%)
DIS   93.69 (+0.53%)
AMC   4.25 (+1.67%)
PFE   40.57 (+1.17%)
PYPL   72.58 (-0.56%)
NFLX   303.59 (+0.03%)
QQQ   305.02 (-0.11%)
AAPL   157.37 (+1.53%)
MSFT   271.24 (-2.93%)
META   196.92 (+0.67%)
GOOGL   101.08 (-0.53%)
AMZN   96.62 (-2.35%)
TSLA   183.21 (+1.71%)
NVDA   259.58 (+0.91%)
NIO   8.66 (+4.84%)
BABA   80.73 (-1.15%)
AMD   95.49 (-2.40%)
T   18.45 (+1.77%)
F   11.23 (-0.62%)
MU   57.14 (+0.85%)
CGC   1.89 (-5.50%)
GE   90.01 (-0.31%)
DIS   93.69 (+0.53%)
AMC   4.25 (+1.67%)
PFE   40.57 (+1.17%)
PYPL   72.58 (-0.56%)
NFLX   303.59 (+0.03%)
QQQ   305.02 (-0.11%)
AAPL   157.37 (+1.53%)
MSFT   271.24 (-2.93%)
META   196.92 (+0.67%)
GOOGL   101.08 (-0.53%)
AMZN   96.62 (-2.35%)
TSLA   183.21 (+1.71%)
NVDA   259.58 (+0.91%)
NIO   8.66 (+4.84%)
BABA   80.73 (-1.15%)
AMD   95.49 (-2.40%)
T   18.45 (+1.77%)
F   11.23 (-0.62%)
MU   57.14 (+0.85%)
CGC   1.89 (-5.50%)
GE   90.01 (-0.31%)
DIS   93.69 (+0.53%)
AMC   4.25 (+1.67%)
PFE   40.57 (+1.17%)
PYPL   72.58 (-0.56%)
NFLX   303.59 (+0.03%)
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$74.34
+0.72 (+0.98%)
(As of 03/20/2023 01:57 PM ET)
Add
Compare
Today's Range
$72.96
$74.51
50-Day Range
$72.01
$86.01
52-Week Range
$65.07
$86.29
Volume
554,473 shs
Average Volume
1.70 million shs
Market Capitalization
$16.57 billion
P/E Ratio
48.91
Dividend Yield
N/A
Price Target
$87.54

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
18.3% Upside
$87.54 Price Target
Short Interest
Healthy
2.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.14mentions of Incyte in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$9.35 M Sold Last Quarter
Proj. Earnings Growth
37.99%
From $3.29 to $4.54 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

29th out of 983 stocks

Commercial Physical Research Industry

3rd out of 16 stocks


INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?
Markets Rise on Powell's Inflation Comments
How Incyte's Alapocas campus could expand
Incyte: Opzelura Is The Main Growth Driver
Incyte: Making Hay While The Sun Shines
Incyte Gets a Quantitative Upgrade
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
2/07/2023
Today
3/20/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,324
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$87.54
High Stock Price Forecast
$113.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+18.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$340.66 million
Pretax Margin
15.59%

Debt

Sales & Book Value

Annual Sales
$3.39 billion
Cash Flow
$2.42 per share
Book Value
$19.64 per share

Miscellaneous

Free Float
183,946,000
Market Cap
$16.41 billion
Optionable
Optionable
Beta
0.74

Social Links


Key Executives

  • Herve HoppenotHerve Hoppenot
    Chairman, President & Chief Executive Officer
  • Christiana Stamoulis
    Chief Financial Officer & Executive Vice President
  • Steven H. SteinSteven H. Stein
    Chief Medical Officer & Executive Vice President
  • Dashyant DhanakDashyant Dhanak
    Chief Scientific Officer & Executive VP
  • Barry FlannellyBarry Flannelly
    EVP & General Manager-North America













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

12 Wall Street analysts have issued 1-year price targets for Incyte's shares. Their INCY share price forecasts range from $63.00 to $113.00. On average, they expect the company's share price to reach $87.54 in the next year. This suggests a possible upside of 18.9% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the start of the year. Since then, INCY stock has decreased by 8.3% and is now trading at $73.62.
View the best growth stocks for 2023 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, February, 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. The biopharmaceutical company earned $926.70 million during the quarter, compared to the consensus estimate of $880.25 million. Incyte had a trailing twelve-month return on equity of 11.45% and a net margin of 10.03%. The company's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.07) EPS.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.05%), Geode Capital Management LLC (1.74%), First Trust Advisors LP (1.52%), Price T Rowe Associates Inc. MD (0.86%), Morgan Stanley (0.85%) and Norges Bank (0.70%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $73.62.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $16.41 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.52 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,324 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 3/20/2023 by MarketBeat.com Staff